Picture Berlin Partner German Biotech Days 2024 in Berlin 650x100px
Document › Details

Metagenomi Inc.. (4/7/21). "Press Release: Metagenomi Extends Series A Financing from RA Capital and Welcomes Andrew Levin to Its Board of Directors". Emeryville, CA.

Organisations Organisation Metagenomi Inc.
  Organisation 2 RA Capital Management L.P.
Products Product genome editing (gene editing)
  Product 2 venture capital
Index terms Index term Metagenomi–SEVERAL: investment, 202104 financing round Series A extension $10m with RA Capital Management closing total Series A at $75m
  Index term 2 Metagenomi–SEVERAL: investment, 202011 financing round Series A $65m co-led by Leaps by Bayer + Humboldt Fund
Persons Person Levin, Andrew (RA Capital Management 202011 Managing Director)
  Person 2 Thomas, Brian C. (Metagenomi 202011 CEO + Co-Founder)

Metagenomi, a gene editing company, today announced the extension and close of its Series A financing, bringing the round to a total of $75 million. This round will support the expansion of the Metagenomi team and development of the company’s therapeutic pipeline. RA Capital Management joins the Series A investor syndicate, including co-lead investors Leaps by Bayer and Humboldt Fund, as well as Sozo Ventures, Agent Capital, InCube Ventures and HOF Capital, following the first close of the Series A financing, which was announced in November 2020. Andrew Levin, MD, Ph.D., Managing Director at RA Capital, will join Metagenomi’s board of directors.

“Metagenomi’s technology and deep scientific foundation in the field of metagenomics enables novel clinical solutions for patients as the company emerges as a new leader in the therapeutic editing field,” noted Dr. Levin. “Where most approaches and pipelines are built on a single system, Metagenomi’s diverse toolbox of gene editing systems will allow the company to match the best technology to unmet medical needs.”

“The RA team adds to the diverse array of expertise at our table as we advance towards the clinic with our in vivo and ex vivo therapies and explore further opportunities for our technologies,” said Brian C. Thomas, Ph.D., Co-Founder and CEO of Metagenomi. “We’re excited and encouraged by the continued interest in Metagenomi we’ve seen from visionary partners in the field and look forward to advancing our goals of curing diseases.”

About Metagenomi

At Metagenomi, we are accelerating innovation in cell and gene therapy with a wave of proprietary CRISPR-based systems to accurately edit DNA where current technologies cannot. Our metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. We adapt and forge these naturally evolved systems into powerful therapeutic tools that can be leveraged by partners and fuel our own pipeline of potentially curative medicines. Our goal is to revolutionize gene editing and unlock its power for the benefit of patients around the world.

About RA Capital Management

RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to provide seed funding to startups and to lead private, IPO, and follow-on financings for its portfolio companies, allowing management teams to drive value creation from inception through commercialization.

Follow us on Twitter: @metagenomi


Ashlye Hodge
+1 (510) 734-4409
Follow us on Twitter: @metagenomi

Record changed: 2023-06-05


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Metagenomi Inc.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Top News Bayer Aignostics Collaboration 650x300px

» top